Compare Enveric Biosciences Inc (ENVB) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Xylem, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Xylem, Inc. trades at $102.47 (market cap $23.77B). The key difference: Xylem, Inc. is far larger — about 3553.1× Enveric Biosciences Inc's market cap, and Xylem, Inc. pays a 1.69% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Xylem, Inc. for 50 Days on average.
| ENVB | XYL | |
|---|---|---|
Market Cap | $6.69M | $23.77B |
Volume | 41,141 | 2,477,250 |
Sector | Health | Industrials |
52-Week High | $10.80 | $152.95 |
52-Week Low | $1.27 | $100.92 |
Typical Hold Time | 14 Days | 50 Days |
Enterprise Value | -$1.60M | $25.55B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Xylem (XYL) trades at $101.99, down 2.48% today, amid bearish technical signals but strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected October 27. Revenue grew from $5.5B in 2022 to $9.04B in 2025, while net income margin expanded to 10.59%. Recent acquisitions of Cornell Pump and Roper Pump strengthen industrial presence.
Outlook remains positive with 47.5% analyst buy ratings and $149.13 consensus price target, representing 46% upside. Key risks include China weakness and higher debt from recent note offerings. The stock offers value with P/E of 24.24 and consistent dividend payments, though technical indicators suggest near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
